The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large compassionate-use protocol.
P. V. Plourde
Employment or Leadership Position - EUSA Pharma
Stock Ownership - EUSA Pharma
S. Jeha
No relevant relationships to disclose
L. B. Silverman
Consultant or Advisory Role - EUSA Pharma
J. B. Nachman
No relevant relationships to disclose
S. R. Rheingold
No relevant relationships to disclose
G. V. H. Dahl
No relevant relationships to disclose
E. A. Raetz
No relevant relationships to disclose
T. Mercedes
Employment or Leadership Position - EUSA Pharma
T. Corn
Employment or Leadership Position - EUSA Pharma
Stock Ownership - EUSA Pharma